ATE209918T1 - Transdermales estradiol/progestogen-pflaster und dessen herstellung - Google Patents

Transdermales estradiol/progestogen-pflaster und dessen herstellung

Info

Publication number
ATE209918T1
ATE209918T1 AT96944042T AT96944042T ATE209918T1 AT E209918 T1 ATE209918 T1 AT E209918T1 AT 96944042 T AT96944042 T AT 96944042T AT 96944042 T AT96944042 T AT 96944042T AT E209918 T1 ATE209918 T1 AT E209918T1
Authority
AT
Austria
Prior art keywords
production
pct
progestogen
patch
transdermal estradiol
Prior art date
Application number
AT96944042T
Other languages
English (en)
Inventor
Guenter Cordes
Antonino Santoro
Ivo Setnikar
Original Assignee
Rotta Res Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rotta Res Bv filed Critical Rotta Res Bv
Application granted granted Critical
Publication of ATE209918T1 publication Critical patent/ATE209918T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AT96944042T 1995-12-22 1996-12-20 Transdermales estradiol/progestogen-pflaster und dessen herstellung ATE209918T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19548332A DE19548332A1 (de) 1995-12-22 1995-12-22 Hormonpflaster
PCT/EP1996/005759 WO1997023227A1 (en) 1995-12-22 1996-12-20 Transdermal estradiol/progestogen agent patch and its production

Publications (1)

Publication Number Publication Date
ATE209918T1 true ATE209918T1 (de) 2001-12-15

Family

ID=7781152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96944042T ATE209918T1 (de) 1995-12-22 1996-12-20 Transdermales estradiol/progestogen-pflaster und dessen herstellung

Country Status (8)

Country Link
US (1) US6153216A (de)
EP (1) EP0868187B1 (de)
JP (1) JP2000502666A (de)
AT (1) ATE209918T1 (de)
AU (1) AU709286B2 (de)
CA (1) CA2239010A1 (de)
DE (2) DE19548332A1 (de)
WO (1) WO1997023227A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615350D0 (en) * 1996-07-22 1996-09-04 Resource Medical Limited Hormone replacement therapy
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
DE19830651A1 (de) * 1998-07-09 2000-01-13 Lohmann Therapie Syst Lts Steroidhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
CA2373171A1 (en) 2000-03-07 2001-09-13 Teijin Limited Stretch plaster
US6800671B1 (en) * 2000-04-21 2004-10-05 Britesmile, Inc. Low peak exotherm curable compositions
ATE355854T1 (de) 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
KR20020035398A (ko) * 2000-11-06 2002-05-11 김윤 수지(手指)용 진통 소염 경피투여제
CN100391462C (zh) * 2001-06-18 2008-06-04 诺芬药品公司 增强的透皮给药***
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
BRPI0414551B8 (pt) 2003-10-10 2021-05-25 Antares Pharma Ipl Ag formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo
US7465729B2 (en) * 2004-04-05 2008-12-16 Sepracor Inc. Methods of treatment of menopause and perimenopause using eszopiclone
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
WO2009158120A2 (en) * 2008-05-30 2009-12-30 Mylan Laboratories Inc. Stabilized transdermal drug delivery system
GB0809905D0 (en) * 2008-06-02 2008-07-09 Secr Defence A Transdermal drug delivery device
EP2742934A1 (de) 2008-10-06 2014-06-18 Mylan Technologies, Inc. Amorphes transdermales Rotigotin-System
JP2012031071A (ja) * 2010-07-28 2012-02-16 Nitto Denko Corp 貼付剤および貼付製剤
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
MX367596B (es) * 2012-01-26 2019-08-27 Therapeuticsmd Inc Tratamientos transdermicos de sustitucion hormonal.
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156080B2 (de) * 1984-03-05 1993-10-20 Nitto Denko Corporation Haftendes Arzneimittelpräparat für perkutane Absorption
CH674618A5 (de) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
ATE101511T1 (de) * 1988-08-02 1994-03-15 Ciba Geigy Ag Mehrschichtiges pflaster.
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
WO1991003219A1 (en) * 1989-09-08 1991-03-21 Cygnus Research Corporation Solid matrix system for transdermal drug delivery
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
US5225199A (en) * 1990-04-24 1993-07-06 Teijin Limited Pharmaceutical plasters
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5198223A (en) * 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
DE4308406C1 (de) * 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
CA2161004C (en) * 1993-04-20 2004-10-26 Wilfried Fischer Active ingredient patch
DE4333595A1 (de) * 1993-10-01 1995-04-06 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Arzneimitteln auf die Haut
GR1002079B (en) * 1994-07-26 1995-12-05 Lavipharm A E System of a special structure and composition for the rapid transdermal administration of oestrogens.

Also Published As

Publication number Publication date
CA2239010A1 (en) 1997-07-03
DE69617732T2 (de) 2002-05-29
US6153216A (en) 2000-11-28
DE19548332A1 (de) 1997-07-10
EP0868187B1 (de) 2001-12-05
JP2000502666A (ja) 2000-03-07
WO1997023227A1 (en) 1997-07-03
AU1377197A (en) 1997-07-17
DE69617732D1 (de) 2002-01-17
EP0868187A1 (de) 1998-10-07
AU709286B2 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
ATE209918T1 (de) Transdermales estradiol/progestogen-pflaster und dessen herstellung
AU5106996A (en) Process for producing active agent preparations in the form of a solid solution of the active agent in a polymer matrix and active agent preparations obtained thereby
IT1274879B (it) Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo.
DK0703802T3 (da) Intravaginalt system til afgivelse af aktivt stof
UA29476C2 (uk) Трансдермальна терапевтична система, що містить естрадіол
TR199501670A2 (tr) Kaplanmis tabletlerin üretilmesi.
WO1999048482A3 (en) Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
AU2386201A (en) Substituted sapogenins and their use
BR9812837A (pt) Processo para fazer um composto, e, composto
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
MX9603516A (es) Derivados de oxima y su uso como pesticidas.
DE69804766T2 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
AU6304796A (en) A process for the production of active substances from unused or discarded devices for the transdermal application of active substances and/or their process waste
DK0863752T3 (da) Anvendelse af alkylaminderivater såsom terbinafin ved fremstillingen af et lægemiddel til behandling af ledsagende sygdomme af en helicobacter pylori-infektion.
EP1351680B8 (de) Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität
SE9404438D0 (sv) New process
IL117083A0 (en) Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical agents containing these compounds
AU5816396A (en) Use of forskolin or extracts containing it in the manufacture of a medicament for the treatment of alcohol addiction
AU5417696A (en) Substituted tetronic acids useful for treating hiv and other retroviruses
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
UA42749C2 (uk) N,n-діетил-8,8-дипропіл-2-азаспіро[4,5]декан-2-пропанамін дималеат, фармацевтична композиція, спосіб лікування

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties